Mineralys Therapeutics, Inc.
MLYS
$-0.73
Change (1 day)
$16.91
Year High
$6.06
Year Low
Categories
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
P/E ratio for Mineralys Therapeutics, Inc. (MLYS)
P/E ratio as of 2023: -4.33
According to Mineralys Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.33. At the end of 2022 the company had a P/E ratio of -25.28.
P/E ratio history for Mineralys Therapeutics, Inc. from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.33 |
| 2022 | -25.28 |
| 2021 | -37.11 |
| 2020 | -210.22 |